专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

41. 发明专利

CA2774919C DOSAGE REGIMEN FOR ADMINISTERING A CD19XCD3 BISPECIFIC ANTIBODY 未知
公开(公告)号：CA2774919C
公开(公告)日：2022-03-08
申请号：CA2774919
申请日：2010-10-27
申请人： MICROMET AG
发明人： KUFER PETER , NAGORSEN DIRK , ZUGMAIER GERHARD , BAEUERLE PATRICK
IPC分类号： A61K39/395 , C07K16/46 , G01N33/574
摘要： The present invention relates to a method for assessing (analyzing) the risk of potential adverse effects for a human patient mediated by the administration of a CD19xCD3 bispecific antibody to said patient comprising determining the ratio of B cells to T cells of said patient, wherein a ratio of about 1:5 or lower is indicative for a risk of potential adverse effects for said patient. Accordingly, the present invention relates a method (dosage regimen) for administering a CD19x CD3 bispecific antibody to a human patient having a B :T cell ratio of about 1:5 or lower, comprising (a) administering a first dose of said antibody for a first period of time; and consecutively (b) administering a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose.In some embodiments, a third dose of said antibody is administered for a third period of time. This dosage regimen can be applied in methods for treating malignant CD19 positive lymphocytes or for ameliorating and/or preventing an adverse effect mediated by the administration of said bispecific antibody. The present invention also relates to the use of a CD19x CD3 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method of the present invention. A pharmaceutical package or kit comprising a first dose and a second dose and optionally a third dose of said antibody as defined in the methods/dosage regimen of the present invention is disclosed as well.

42. 发明专利

CA2633594C MEANS AND METHODS FOR THE TREATMENT OF TUMOROUS DISEASES 未知
公开(公告)号：CA2633594C
公开(公告)日：2021-10-26
申请号：CA2633594
申请日：2006-11-29
申请人： MICROMET AG
发明人： BAEUERLE PATRICK , KUFER PETER , KLINGER MATTHIAS , LEO EUGEN
IPC分类号： C07K16/46 , A61K39/395 , A61P35/02 , C07K16/28
摘要： Provided are pharmaceutical means and methods for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia comprising the administration of a bispecific single chain antibody construct to a subject in the need thereof and the use of said bispecific single chain antibody construct for the preparation of a pharmaceutical composition for the prevention, treatment or amelioration of indolent or aggressive B cell non-Hodgkin lymphoma (B NHL) and B cell leukemia, whereby said construct is to be administered for at least 1 week in specified daily doses. Moreover, the invention relates to kits comprising a bispecific single chain antibody construct to be used in accordance with this invention.

43. 发明专利

CA2522586C PHARMACEUTICAL COMPOSITIONS COMPRISING BISPECIFIC ANTI-CD3, ANTI-CD19 ANTIBODY CONSTRUCTS FOR THE TREATMENT OF B-CELL RELATED DISORDERS 未知
公开(公告)号：CA2522586C
公开(公告)日：2017-02-21
申请号：CA2522586
申请日：2004-05-26
申请人： MICROMET AG
发明人： KUFER PETER , LUTTERBUESE RALF , KOHLEISEN BIRGIT , ZEMAN STEVEN , BAEUERLE PATRICK
IPC分类号： A61K48/00 , A61K39/395 , A61P19/02 , A61P31/00 , A61P33/00 , A61P35/00 , A61P35/02 , A61P37/02 , C07K16/28 , C12N15/13
摘要： The present invention relates to a pharmaceutical composition comprising a bispecific single chain antibody construct, said bispecific single chain antibody construct comprising binding domains specific for human CD3 and human CD19, wherein the corresponding variable heavy chain regions (VH) and the corresponding variable light chain regions (VL) regions are arranged, from N-terminus to C-terminus, in the order, VH(CD19)-VL(CD19)-VH(CD3)-VL(CD3), VH(CD3)-VL-(CD3)-~VH(CD19)-VL(CD19) or VH(CD3)-VL(CD3)-VL(CD19)-VH(CD19). Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CD19 antigen are disclosed.

44. 发明专利

CA2544562C BISPECIFIC ANTIBODIES 未知
公开(公告)号：CA2544562C
公开(公告)日：2013-10-15
申请号：CA2544562
申请日：2004-12-22
申请人： MICROMET AG
发明人： KUFER PETER , BERRY MEERA , BAEUERLE PATRICK , ITIN CHRISTIAN
IPC分类号： C07K16/46 , A61K39/395 , A61P35/00 , C07K14/705 , C07K16/28 , C07K16/30 , C12N15/13 , C12N15/85
摘要： A bispecific antibody comprising two antibody variable domains on a single polypeptide chain, wherein a first portion of the bispecific antibody is capable of recruiting the activity of a human immune effector cell by specifically binding to an effector antigen on the human immune effector cell, said first portion consisting of one antibody variable domain, and a second portion of the bispecific antibody specifically binds to a target antigen other than the effector antigen, said target antigen on a target cell other than said human immune effector cell, and said second portion comprising one antibody variable domain.

45. 发明专利

CA2522894C PHARMACEUTICAL COMPOSITION COMPRISING A BISPECIFIC ANTIBODY SPECIFIC FOR EPCAM 未知
公开(公告)号：CA2522894C
公开(公告)日：2013-06-25
申请号：CA2522894
申请日：2004-05-26
申请人： MICROMET AG
发明人： KUFER PETER , BERRY MEERA , OFFNER SONJA , BRISCHWEIN KLAUS , WOLF ANDREAS , RAUM TOBIAS , KOHLEISEN BIRGIT , LENKKERI-SCHUTZ ULLA , BAUERLE PATRICK
IPC分类号： A61K48/00 , A61K39/395 , A61P35/00 , C07K16/28 , C07K16/30 , C12N15/13 , C12P21/00
摘要： The present invention provides a pharmaceutical composition comprising a bispecific single chain antibody construct. Said bispecific single chain antibody construct is characterized to comprise or consist of at least two domains, whereby one of said at least two domains specifically binds to human EpCAM and comprises at least one CDR-H3 region comprising the amino acid sequence NXID antigen and a second domain binds to human CD3 antigen. The invention further provides a process for the production of the pharmaceutical composition of the invention, a method for the prevention, treatment or amelioration of a tumorous disease and the use of the disclosed bispecific single chain antibody construct and corresponding means in the prevention, treatment or amelioration of a tumorous disease.

46. 发明专利

ES2390243T3 Agentes de unión biespecíficos específicos de especies cruzadas 未知
公开(公告)号：ES2390243T3
公开(公告)日：2012-11-07
申请号：ES08735000
申请日：2008-04-03
申请人： MICROMET AG , AMGEN RES MUNICH GMBH
发明人： KLINGER MATTHIAS , RAUM TOBIAS , RAU DORIS , MANGOLD SUSANNE , KISCHEL ROMAN , LUTTERBUESE RALF , HOFFMANN PATRICK , KUFER PETER
IPC分类号： C07K16/28 , C07K14/705 , C07K16/30 , C07K16/32 , C07K16/42 , C07K16/46
摘要： Un polipéptido que comprende un primer dominio de unión que es un anticuerpo capaz de unirse a un epítopode la cadena CD3ε humana y de Callithrix jacchus, Saguinus oedipus o Saimiri sciureus, en la que el epítopo formaparte de una secuencia de aminoácidos comprendida en el grupo que consiste en las SEQ ID NO: 2, 4, 6 u 8 ycomprende al menos la secuencia de aminoácidos Gln-Asp-Gly-Asn-Glu, y un segundo dominio de unión capaz deunirse a EGFR, Her2/neu o IgE de un ser humano y/o de un primate distinto de chimpancé.

47. 发明专利

AU2011234443A1 Cross-species-specific PSMAxCD3 bispecific single chain antibody 未知
公开(公告)号：AU2011234443A1
公开(公告)日：2012-09-27
申请号：AU2011234443
申请日：2011-04-01
申请人： MICROMET AG
发明人： KUFER PETER
IPC分类号： C07K16/28 , A61K39/395 , C07K16/30 , C07K16/40
摘要： The present invention relates to a bispecific single chain antibody molecule comprising a first binding domain capable of binding to an epitope of human and non-chimpanzee primate CD3 epsilon chain, wherein the epitope is part of an amino acid sequence comprised in the group consisting of SEQ ID NOs. 2, 4, 6, and 8, and a second binding domain capable of binding to prostate-specific membrane antigen (PSMA). The invention also provides nucleic acids encoding said bispecific single chain antibody molecule as well as vectors and host cells and a process for its production. The invention further relates to pharmaceutical compositions comprising said bispecific single chain antibody molecule and medical uses of said bispecific single chain antibody molecule.

48. 发明专利

BRPI0620632A2 未知
公开(公告)号：BRPI0620632A2
公开(公告)日：2011-12-20
申请号：BRPI0620632
申请日：2006-12-21
申请人： MICROMET AG
发明人： LUTTERBUESE RALF , MAYER PETRA , SHALLER EVELYNE , RAU DORIS , MANGOLD SUSANNE , KUFER PETER , MURR ALEXANDER , WISSINGER MONIKA , RAUM TOBIAS
IPC分类号： C07K16/24 , A61K39/395 , C07K16/30
摘要： The present invention relates to pharmaceutical compositions for the treatment of an epithelial tumor in a human, said pharmaceutical composition comprising a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, wherein said second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7. Furthermore, processes for the production of said pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.

49. 发明专利

BRPI0620639A2 未知
公开(公告)号：BRPI0620639A2
公开(公告)日：2011-11-22
申请号：BRPI0620639
申请日：2006-12-21
申请人： MICROMET AG , MEDIMMUNE INC
发明人： KINCH MICHAEL , ROFF SHANNON , KUFER PETER , BRUCKHEIMER ELIZABETH , SCHLERETH BERND , HAMMOND SCOTT A , LUTTERBUESE RALF , KIENER PETER A , BAEURELE PATRICK , LUTTERBUESE PETRA
IPC分类号： A61K39/00 , C12P21/08

50. 发明专利

CA2774732A1 DOSAGE REGIMEN FOR ADMINISTERING AN EPCAMXCD3 BISPECIFIC ANTIBODY 未知
公开(公告)号：CA2774732A1
公开(公告)日：2011-03-24
申请号：CA2774732
申请日：2010-09-20
申请人： MICROMET AG
发明人： ZUGMEIER GERHARD , KUFER PETER , RUETTINGER DOMINIK , KAUBITZSCH SABINE
IPC分类号： A61K39/395 , A61P35/00 , C07K16/28 , C07K16/30 , C07K16/46
摘要： The present invention relates to a method (dosage regimen) for administering an EpCAMxCD3 bispecific antibody to a human patient, comprising (a) administering continually a first dose of said antibody for a first period of time; and consecutively (b) administering continually a second dose of said antibody for a second period of time, wherein said second dose exceeds said first dose. The methods of the invention (and likewise the dosage regimen of the invention) are also suitable for treating EpCAM positive epithelial cancer cells in a human patient, or for ameliorating and/or preventing a medical condition mediated by the continued administration of an EpCAMxCD3 bispecific antibody to a human patient. The present invention also relates to the use of an EpCAMxCD3 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method as defined in any one of the preceding claims. A pharmaceutical package or kit comprising the first dose and the second dose as defined in the methods/dosage regimen of the present invention is disclosed as well.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式